|Bid||97.01 x 1000|
|Ask||0.00 x 800|
|Day's range||96.42 - 99.94|
|52-week range||88.00 - 188.99|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||5.09|
|Earnings date||06 Nov 2023|
|Forward dividend & yield||2.11 (1.32%)|
|Ex-dividend date||02 Jun 2022|
|1y target est||143.10|
The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the two coronavirus vaccine makers. Moderna said in a statement that it disagreed with the office's decision and would lodge an appeal. Shares in Moderna were down 2.3% in premarket trading on Wall Street after the decision was announced by BioNTech earlier on Tuesday.
COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer. "We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted," it added.
BioNTech SE (NASDAQ:BNTX) Q3 2023 Earnings Call Transcript November 6, 2023 BioNTech SE beats earnings expectations. Reported EPS is $0.67, expectations were $-0.53. Operator: Welcome to the BioNTech Third Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead. […]